The HIV shot that could change medicine is facing its biggest test: Getting to patients

Lenacapavir, a twice-yearly HIV prevention shot developed by Gilead Sciences, shows near 100% efficacy in trials but faces access challenges in Latin America due to high costs. Upper-middle-income countries like Brazil, Mexico, Argentina, and Peru cannot afford the US price of $14,000 per dose, while generic versions are available at $40 in 120 other countries. Protests and criticism have emerged over pricing disparities, with activists and officials demanding equitable access.